Ann Tanabe gives a preview of the 12th annual Texas Life Science Forum from Houston.

Rishi Bedi explains how AI might be impacting protein design, genetic medicine, immuno-oncology and more in the future.

Dr. Chen talks about emerging technologies he is excited about such logic gating, AI, and multi-specific nanobots.

Paul Rennert gives an update on Aleta, and summarizes data at #SITC23 from the IO 2.0, cytokine, TGF beta, Treg, lymphoid, and CAR-T spaces.

Zen Su gives an overview Marengo, his view of #SITC23, and SITC's new biotech initiative.

John Connolly describes trends he is seeing in cell therapy, bi-specific engagers, myeloid checkpoint targets, and combinations.

Dr. Hege discusses the latest in cell therapy, new modalities, and a biotech initiative that SITC is launching.

Mara Goldstein describes what she is watching for at the conference and discusses Iovance, Xencor, Syndax, Autolus, and more.

Dr. Shawver describes how Capstan plans to achieve in-vivo CAR-T by utilizing LNPs to deliver mRNA to lymphocytes in the body.

Dr. Topol discusses the latest in COVID, GLP-1s, NASH, CRISPR, and AI in medicine.

Sarah Boyce explains the rationale for using AOCs against muscle disorders like Myotonic dystrophy type 1 and DMD.

Kelly Cloud describes the assets, infrastructure, and incentives that the Dallas area offers life sciences companies.

BioNTX CEO Kathleen Otto gives us a summary of the biotech activity in North Texas.

Alex Thompson gives a deep dive into the I&I space and discusses Apogee, Aeglea, argenx, Immunovant, Aclaris, Morphic, and Ventyx.

Larry Tiffany describes how GenrAb is leveraging neurodegenerative stress and immunoogenetic models from UTSW for antibody discovery.

Marty Driscoll describes how OncoNano is utilizing a tumor's acidic environment to develop therapies and imaging agents.

Vinny Jindal describes Secretome's approach to using neonatal cardiac progenitor cells.

Dan Siegwart describes what goes into getting LNPs to places in the body beyond the liver, and how he has co-founded ReCode Therapeutics.

Claire Aldridge explains how Form Bio was derived from the work that Colossal Bio was doing in Texas.

Dr. Olson describes work that has come out of his lab that aims to help diseases such as muscular dystrophy and hypertrophic cardiomyopathy.